Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma

New York University, New York

St. Lukes Rossevelt Hospital, New York

UNC School of Medicine, Chapel Hill

H. Lee Moffit Cancer Center, Tampa

Cooper Green Hospital / Jefferson Clinic P.C., Birmingham

Memphis Cancer Center, PC, Memphis

Kentuckiana Cancer Institute, PLLC, Louisville

Ohio State University Medical Center, Columbus

West Michigan Regional Cancer and Blood Center, Ludington

Rush Cancer Institute, Chicago

Bond Clinic Inc., Rolla

Arkansas Cancer Center, Pine Bluff

University of Texas Health Sciences Center at San Antonio, San Antonio

Arizona Cancer Center, Tucson

Nevada Cancer Center, Las Vegas

USC/Norris Comprehensive Cancer Center, Los Angeles

City of Hope Medical Group, Pasadena

Alta Bates Comprehensive Cancer Center, Berkley

California Cancer Center, Greenbrae

Oregon Health Sciences, Portland

Norris Cotton Cancer Center, Lebanon

The Cancer Institute of New Jersey, New Brunswick